Cargando…
Risk of subclinical atherosclerosis across metabolic transition in individuals with or without fatty liver disease: a prospective cohort study
BACKGROUND: Metabolic dysfunction is a major determinant in the progression of fatty liver disease. It is pivotal to evaluate the metabolic status and subsequent transition in fatty liver population and to identify the risk of subclinical atherosclerosis. METHODS: The prospective cohort study includ...
Autores principales: | Xin, Zhuojun, Huang, Jiaojiao, Cao, Qiuyu, Wang, Jialu, He, Ruixin, Hou, Tianzhichao, Ding, Yi, Lu, Jieli, Wang, Tiange, Zhao, Zhiyun, Wang, Weiqing, Ning, Guang, Xu, Min, Bi, Yufang, Xu, Yu, Li, Mian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007748/ https://www.ncbi.nlm.nih.gov/pubmed/36899397 http://dx.doi.org/10.1186/s12986-023-00734-3 |
Ejemplares similares
-
Nonalcoholic fatty liver disease in relation to the remission and progression along the glycemic continuum
por: Xin, Zhuojun, et al.
Publicado: (2022) -
Age-specific difference in the association between prediabetes and subclinical atherosclerosis: an analysis of a chinese prospective cohort study
por: Cao, Qiuyu, et al.
Publicado: (2022) -
Individual and Combined Associations of Glucose Metabolic Components With Cognitive Function Modified by Obesity
por: He, Ruixin, et al.
Publicado: (2021) -
Urinary albumin-to-creatinine ratio levels are associated with subclinical atherosclerosis and predict CVD events and all-cause deaths: a prospective analysis
por: Liu, Shanshan, et al.
Publicado: (2021) -
SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study
por: Xu, Min, et al.
Publicado: (2022)